Meghan Fitzgerald bought stock once, on Mar 17, 2020

Meghan M. Fitzgerald is a seasoned healthcare executive, investor, and academic serving as an Independent Director at Roivant Sciences Ltd. (ROIV) since March 12, 2023, where she sits on the audit committee( She recently exercised 70,000 stock options at $8.80 per share and sold the shares at a weighted average of $27.45, retaining 42,963 common shares( Founder of K2 HealthVentures (2018) and Grey Ghost Capital, she also advises firms like Goldman Sachs, TowerBrook Capital, and Wellspring Capital Management, and chairs the NCG committee at Tenet Healthcare Corp. (since 2018)(

Fitzgerald's career highlights include EVP of Strategy and M&A at Cardinal Health, growing its Specialty Solutions from $700M to over $8B; President-Specialty Solutions at Cardinal Health (2015-2016); and senior roles at Pfizer, Merck, Medco, and LetterOne Holdings( Holding a DrPH from New York Medical College, MPH from Columbia University, BSN from Fairfield University, and MSN earned during the pandemic, she is an Assistant Professor of Health Policy at Columbia (since 2014) and author of Ascending Davos(

Written by Perplexity from public sources.